Posted by Michael Wonder on 26 Oct 2023
Oncternal Therapeutics announces FDA granted fast track designation for ONCT-534 for the treatment of metastatic castration-resistant prostate cancer
26 October 2023 - Oncternal Therapeutics today announced that the US FDA has designated ONCT-534, its novel dual-acting androgen receptor inhibitor, as a fast track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer resistant to approved androgen receptor pathway inhibitors.
ONCT-534 interacts with both the N-terminal domain and the ligand-binding domain of the androgen receptor, inhibiting cell growth and inducing androgen receptor degradation.
